Artículos

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features / Anthony J. Rothschild en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 365-373 Título : A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features Tipo de documento: texto impreso Autores: Anthony J. Rothschild, Autor ; Douglas E. Williamson, Autor ; Mauricio Tohen, Autor Fecha de publicación: 2023 Artículo en la página: pp. 365-373 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Benzodiacepinas, Trastorno Depresivo Mayor, Trastorno depresivo mayor, Fluoxetina, Trastornos psicóticos. Resumen: The purpose of this study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted at 27 sites. Patients (n = 124 trial 1, n = 125 trial 2) were randomized to 1 of 3 treatment groups: OLZ (5 to 20 mg/d), PLA, or OFC (olanzapine 5 to 20 mg/d + fluoxetine 20 to 80 mg/d). Link: ./index.php?lvl=notice_display&id=30948 [artículo] A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features [texto impreso] / Anthony J. Rothschild, Autor ; Douglas E. Williamson, Autor ; Mauricio Tohen, Autor . - 2023 . - pp. 365-373. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 365-373 Palabras clave: Benzodiacepinas, Trastorno Depresivo Mayor, Trastorno depresivo mayor, Fluoxetina, Trastornos psicóticos. Resumen: The purpose of this study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted at 27 sites. Patients (n = 124 trial 1, n = 125 trial 2) were randomized to 1 of 3 treatment groups: OLZ (5 to 20 mg/d), PLA, or OFC (olanzapine 5 to 20 mg/d + fluoxetine 20 to 80 mg/d). Link: ./index.php?lvl=notice_display&id=30948

Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder / Eduard Vieta i Pascual en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 374-378 Título : Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder Tipo de documento: texto impreso Autores: Eduard Vieta i Pascual, Autor ; José Sánchez-Moreno, Autor ; José M. Goikolea, Autor Fecha de publicación: 2023 Artículo en la página: pp. 374-378 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Benzodiacepinas, Trastorno bipolar, Terapia con medicamentos, Fructosa. Resumen: Olanzapine is an effective drug for the long-term treatment of bipolar disorder but is associated with burdensome weight gain. Topiramate is a novel anticonvulsant that may induce weight loss in some patients. This is the first study to address the long-term efficacy and impact on weight of the combination of olanzapine and topiramate in bipolar patients. Link: ./index.php?lvl=notice_display&id=30949 [artículo] Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder [texto impreso] / Eduard Vieta i Pascual, Autor ; José Sánchez-Moreno, Autor ; José M. Goikolea, Autor . - 2023 . - pp. 374-378. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 374-378 Palabras clave: Benzodiacepinas, Trastorno bipolar, Terapia con medicamentos, Fructosa. Resumen: Olanzapine is an effective drug for the long-term treatment of bipolar disorder but is associated with burdensome weight gain. Topiramate is a novel anticonvulsant that may induce weight loss in some patients. This is the first study to address the long-term efficacy and impact on weight of the combination of olanzapine and topiramate in bipolar patients. Link: ./index.php?lvl=notice_display&id=30949

Testosterone versus fluoxetine for depression and fatigue in hiv/aids / Judith G. Rabkin en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 379-385 Título : Testosterone versus fluoxetine for depression and fatigue in hiv/aids : A placebo-controlled trial Tipo de documento: texto impreso Autores: Judith G. Rabkin, Autor ; Glenn J. Wagner, Autor ; Martin C. McElhiney, Autor Fecha de publicación: 2023 Artículo en la página: pp. 379-385 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Síndrome de Inmunodeficiencia Adquirida, Trastorno Depresivo, Fatiga, Fluoxetina, Testosterona. Resumen: While testosterone's ameliorative effects on depressive disorders and fatigue in HIV-positive patients have been suggested in the literature, no placebo-controlled trial selecting for depressive disorders and including a standard antidepressant has been conducted. Link: ./index.php?lvl=notice_display&id=30950 [artículo] Testosterone versus fluoxetine for depression and fatigue in hiv/aids : A placebo-controlled trial [texto impreso] / Judith G. Rabkin, Autor ; Glenn J. Wagner, Autor ; Martin C. McElhiney, Autor . - 2023 . - pp. 379-385. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 379-385 Palabras clave: Síndrome de Inmunodeficiencia Adquirida, Trastorno Depresivo, Fatiga, Fluoxetina, Testosterona. Resumen: While testosterone's ameliorative effects on depressive disorders and fatigue in HIV-positive patients have been suggested in the literature, no placebo-controlled trial selecting for depressive disorders and including a standard antidepressant has been conducted. Link: ./index.php?lvl=notice_display&id=30950

Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder / Padideh Ghaeli en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 386-388 Título : Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder Tipo de documento: texto impreso Autores: Padideh Ghaeli, Autor ; Esmail Shahsavand, Autor ; Mojdeh Mesbahi, Autor Fecha de publicación: 2023 Artículo en la página: pp. 386-388 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Ayuno - sangre, Fluoxetina, Imipramina. Resumen: This study was designed to compare the effects of fluoxetine and imipramine on fasting blood glucose (FBG) in patients with major depressive disorder. Sixty nondiabetic patients with major depressive disorder (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this randomized, double-blind study. Link: ./index.php?lvl=notice_display&id=30951 [artículo] Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder [texto impreso] / Padideh Ghaeli, Autor ; Esmail Shahsavand, Autor ; Mojdeh Mesbahi, Autor . - 2023 . - pp. 386-388. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 386-388 Palabras clave: Trastorno depresivo mayor, Ayuno - sangre, Fluoxetina, Imipramina. Resumen: This study was designed to compare the effects of fluoxetine and imipramine on fasting blood glucose (FBG) in patients with major depressive disorder. Sixty nondiabetic patients with major depressive disorder (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this randomized, double-blind study. Link: ./index.php?lvl=notice_display&id=30951

Duloxetine in the treatment of depression A double-blind placebo-controlled comparison with paroxetine / David J. Goldstein en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 389-399 Título : Duloxetine in the treatment of depression A double-blind placebo-controlled comparison with paroxetine Tipo de documento: texto impreso Autores: David J. Goldstein, Autor ; Yili Lu, Autor ; Michael J. Detke, Autor Fecha de publicación: 2023 Artículo en la página: pp. 389-399 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Paroxetina, Trastornos de inicio y mantenimiento del sueño, Trastornos de iniciación y mantenimiento del sueño, Tiofenos. Resumen: Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder. Link: ./index.php?lvl=notice_display&id=30952 [artículo] Duloxetine in the treatment of depression A double-blind placebo-controlled comparison with paroxetine [texto impreso] / David J. Goldstein, Autor ; Yili Lu, Autor ; Michael J. Detke, Autor . - 2023 . - pp. 389-399. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 389-399 Palabras clave: Trastorno depresivo mayor, Paroxetina, Trastornos de inicio y mantenimiento del sueño, Trastornos de iniciación y mantenimiento del sueño, Tiofenos. Resumen: Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder. Link: ./index.php?lvl=notice_display&id=30952

Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy / Walter W. van den Broek en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 400-403 Título : Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy Tipo de documento: texto impreso Autores: Walter W. van den Broek, Autor ; Ariejan de Lely, Autor ; Paul G. Mulder, Autor Fecha de publicación: 2023 Artículo en la página: pp. 400-403 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Trastorno depresivo, Resistencia a los medicamentos, Terapia Electroconvulsiva. Resumen: This prospective study assessed the influence of resistance to antidepressant pharmacotherapy on the short-term response to subsequent electroconvulsive therapy (ECT). Previous research has shown that patients with medication resistance were less likely to respond to ECT. This finding may be applicable to the population of depressed inpatients in The Netherlands, where ECT is often preceded by several medication trials. Link: ./index.php?lvl=notice_display&id=30953 [artículo] Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy [texto impreso] / Walter W. van den Broek, Autor ; Ariejan de Lely, Autor ; Paul G. Mulder, Autor . - 2023 . - pp. 400-403. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 400-403 Palabras clave: Antidepresivos, Trastorno depresivo, Resistencia a los medicamentos, Terapia Electroconvulsiva. Resumen: This prospective study assessed the influence of resistance to antidepressant pharmacotherapy on the short-term response to subsequent electroconvulsive therapy (ECT). Previous research has shown that patients with medication resistance were less likely to respond to ECT. This finding may be applicable to the population of depressed inpatients in The Netherlands, where ECT is often preceded by several medication trials. Link: ./index.php?lvl=notice_display&id=30953

Brief evaluation of medication influences and beliefs Development and testing of a brief scale for medication adherence / Christian R. Dolder en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 404-409 Título : Brief evaluation of medication influences and beliefs Development and testing of a brief scale for medication adherence Tipo de documento: texto impreso Autores: Christian R. Dolder, Autor ; Jonathan P. Lacro, Autor ; Kathleen A. Warren, Autor Fecha de publicación: 2023 Artículo en la página: pp. 404-409 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Cultura, Cumplimiento del paciente, Esquizofrenia, Estadística no paramétrica Resumen: The purpose of this study was to develop and test a brief scale (Brief Evaluation of Medication Influences and Beliefs [BEMIB]) designed to identify patients who are more likely to be nonadherent to their antipsychotic medication. Link: ./index.php?lvl=notice_display&id=30954 [artículo] Brief evaluation of medication influences and beliefs Development and testing of a brief scale for medication adherence [texto impreso] / Christian R. Dolder, Autor ; Jonathan P. Lacro, Autor ; Kathleen A. Warren, Autor . - 2023 . - pp. 404-409. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 404-409 Palabras clave: Antipsicóticos, Cultura, Cumplimiento del paciente, Esquizofrenia, Estadística no paramétrica Resumen: The purpose of this study was to develop and test a brief scale (Brief Evaluation of Medication Influences and Beliefs [BEMIB]) designed to identify patients who are more likely to be nonadherent to their antipsychotic medication. Link: ./index.php?lvl=notice_display&id=30954

Alprazolam attenuates the behavioral effects of d-amphetamine in humans / Craig R. Rush en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 410-420 Título : Alprazolam attenuates the behavioral effects of d-amphetamine in humans Tipo de documento: texto impreso Autores: Craig R. Rush, Autor ; William W. Stoops, Autor ; Frances P. Wagner, Autor Fecha de publicación: 2023 Artículo en la página: pp. 410-420 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Afecto, Alprazolam, Dextroanfetamina, Discriminación psicológica, Rendimiento psicomotor. Resumen: The results of preclinical behavioral pharmacology studies suggest that γ-aminobutyric acidA (GABAA) receptor modulators attenuate the behavioral effects of commonly abused stimulants such as amphetamines and cocaine under a variety of behavioral arrangements including drug discrimination and self-administration. Link: ./index.php?lvl=notice_display&id=30955 [artículo] Alprazolam attenuates the behavioral effects of d-amphetamine in humans [texto impreso] / Craig R. Rush, Autor ; William W. Stoops, Autor ; Frances P. Wagner, Autor . - 2023 . - pp. 410-420. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 410-420 Palabras clave: Afecto, Alprazolam, Dextroanfetamina, Discriminación psicológica, Rendimiento psicomotor. Resumen: The results of preclinical behavioral pharmacology studies suggest that γ-aminobutyric acidA (GABAA) receptor modulators attenuate the behavioral effects of commonly abused stimulants such as amphetamines and cocaine under a variety of behavioral arrangements including drug discrimination and self-administration. Link: ./index.php?lvl=notice_display&id=30955

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence / Raymond F. Anton en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 421-428 Título : A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence Tipo de documento: texto impreso Autores: Raymond F. Anton, Autor ; Helen Pettinati, Autor ; Allen Zweben, Autor Fecha de publicación: 2023 Artículo en la página: pp. 421-428 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alcoholismo, Relación Dosis-Respuesta, Naltrexona - efectos adversos Resumen: The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Link: ./index.php?lvl=notice_display&id=30956 [artículo] A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence [texto impreso] / Raymond F. Anton, Autor ; Helen Pettinati, Autor ; Allen Zweben, Autor . - 2023 . - pp. 421-428. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 421-428 Palabras clave: Alcoholismo, Relación Dosis-Respuesta, Naltrexona - efectos adversos Resumen: The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Link: ./index.php?lvl=notice_display&id=30956

A comparison of risperidone-induced weight gain across the age span / Daniel J. Safer en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 429-436 Título : A comparison of risperidone-induced weight gain across the age span Tipo de documento: texto impreso Autores: Daniel J. Safer, Autor Fecha de publicación: 2023 Artículo en la página: pp. 429-436 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Envejecimiento, Risperidona, Aumento de peso - efectos del medicamento. Resumen: A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span. The review and pooled data analyses were based on double-blind, open trial, and case series studies containing findings on drug dose, age of subjects, weight gain, duration of treatment, and if available, baseline body weight, body mass index, and the percent of subjects experiencing a prominent RIS-induced weight gain. Link: ./index.php?lvl=notice_display&id=30957 [artículo] A comparison of risperidone-induced weight gain across the age span [texto impreso] / Daniel J. Safer, Autor . - 2023 . - pp. 429-436. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 4 (Agosto) . - pp. 429-436 Palabras clave: Envejecimiento, Risperidona, Aumento de peso - efectos del medicamento. Resumen: A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span. The review and pooled data analyses were based on double-blind, open trial, and case series studies containing findings on drug dose, age of subjects, weight gain, duration of treatment, and if available, baseline body weight, body mass index, and the percent of subjects experiencing a prominent RIS-induced weight gain. Link: ./index.php?lvl=notice_display&id=30957